๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
By invitation
Optimal Interval for Periodic Alveolar Recruitment Maneuvers Achieving 90% Lung Re-expansion During Intraoperative Ventilation
NCT07239557Major Abdominal Surgery, Atelectasis, Lung-protective Ventilation, Lung Ultrasound Score
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
52
Guangzhou
2025-12-10
Recruiting
Direct Visualization ERAT Versus Laparoscopic Appendectomy in Adults With Acute Uncomplicated Appendicitis
NCT07230379Acute Uncomplicated Appendicitis
Changhai Hospital
Not applicable
376
Chongqing, Guangzhou, Shenzhen, Kaifeng, Zhengzhou, Changsha, Suzhou, Nanchang
2025-12-10
Recruiting
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
NCT07265570Ulcerative Colitis
InSilico Medicine Hong Kong Limited
Phase 2
80
Beijing, Chongqing, Guangzhou, Huizhou, Nanning, Shijiazhuang, Luoyang, Xinxiang
2025-12-10
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
AbbVie
Phase 2/3
490
Guangzhou, Nanchang, Shanghai, รœrรผmqi
2025-12-10
Recruiting
The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients
NCT07275632Delayed Graft Function, Kidney Transplantation
First Affiliated Hospital of Chongqing Medical University
Phase 1/2
47
Chongqing, Guangzhou
2025-12-10
Recruiting
Effects of BLa80 and LRa05 on the Gut Microbiota Metabolite Profile of Healthy Individuals
NCT07287306Healthy Individuals
Wecare Probiotics Co., Ltd.
Not applicable
375
Guangzhou
2025-12-10
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
NCT07179679Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Recruiting
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07226999Small Cell Lung Cancer (SCLC)
Pfizer
Phase 2/3
550
Guangzhou, Shanghai
2025-12-09
Recruiting
A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders
NCT06904027Urea Cycle Disorders
Tongji Hospital
Observational
40
Beijing, Guangzhou, Wuhan, Shanghai, Hangzhou
2025-12-09
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Beijing, Chengdu, Guangzhou, Luoyang, Shanghai, Xuzhou
2025-12-08
Recruiting
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
NCT07534033NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection, Overall Lung Function is Adequate for the Planned Lung Resection, AJCC is Classified as IB-IIIC
Zhujiang Hospital
Phase 2
46
Guangzhou
2025-12-06
Recruiting
Endoscopic Skin-Sparing vs. Conventional Mastectomy for Wound Complications in BC
NCT07548762Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
258
Guangzhou
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
Takeda
Phase 3
110
Beijing, Guangzhou, Changsha, Hangzhou, Shanghai
2025-12-04
Recruiting
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
NCT07255404Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE
Phase 2
105
Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming
2025-12-04
Recruiting
Association Between Clinical Classification and Prognosis in Chronic Radiation Enteropathy
NCT07378631Radiotherapy, Radiation Proctitis, Radiation Enteritis
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
150
Guangzhou
2025-12-04
Recruiting
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo
Phase 1
60
Guangzhou, Shanghai, Wenzhou
2025-12-03
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 3
500
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
GlaxoSmithKline
Phase 3
450
Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2025-12-03
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
Bristol-Myers Squibb
Phase 3
366
Beijing, Guangzhou, Shenzhen, Handan, Zhengzhou, Changsha, Jinan, Shanghai
2025-12-03
Recruiting
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
NCT07229612Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
200
Guangzhou
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Recruiting
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT07165951Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Recruiting
A Study of LBL-024 in Combination With Paclitaxel ยฑ Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
NCT07042802Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Recruiting
Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease
NCT07363538Complex Congenital Heart Disease
Central China Fuwai Hospital of Zhengzhou University
Not applicable
738
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao
2025-12-01
Recruiting
Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC
NCT07626736Nonsmall Cell Lung Cancer
Wen-zhao ZHONG
Not applicable
300
Guangzhou
2025-12-01
Recruiting
Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety
NCT07216014Crohn's Disease and Ulcerative Colitis
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 4
200
Guangzhou
2025-12-01
Recruiting
Human Sinonasal Mucosa Heterogeneity Study
NCT07692243Human Sinonasal Mucosal Spatial Atlas
First Affiliated Hospital, Sun Yat-Sen University
Observational
100
Guangzhou
2025-12-01
Recruiting
DEB-TACE vs cTACE in HCC After TIPS
NCT07322848Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
First Affiliated Hospital, Sun Yat-Sen University
Phase 3
206
Guangzhou
2025-12-01
Recruiting
Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
NCT07436845Hepatocellular Carcinoma (HCC), Emotional Distress, HAIC(Hepatic Artery Infusion Chemotherapy), Immunotherapy
Nanfang Hospital, Southern Medical University
Observational
90
Guangzhou
2025-12-01
Not yet open
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
NCT07261709Refractory Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2
236
Guangzhou
2025-12-01
Recruiting
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
NCT07246564Myasthenia Gravis
UCB Biopharma SRL
Phase 4
40
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen
2025-12-01
Not yet open
Intravenous Tirofiban After Delayed Thrombolysis in Stroke
NCT07111806Acute Ischemic Stroke
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
852
Guangzhou
2025-12-01
Recruiting
Association Between Preoperative Metformin Exposure and Postoperative Nausea and Vomiting in Patients Undergoing General Anesthesia
NCT07244575Postoperative Nausea and Vomiting
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
909
Guangzhou
2025-12-01
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Eli Lilly and Company
Phase 3
7,140
Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou
2025-12-01
Recruiting
Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound
NCT07357571Thyroid Papillary Carcinoma, Contrast Enhanced Ultrasound
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
600
Guangdong, Guangzhou
2025-12-01
Active, closed
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis
NCT07232576Adult Patients With Moderately to Severely Active Ulcerative Colitis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
21
Guangzhou
2025-12-01
Not yet open
Exploratory Study of Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Ischemic Stroke
NCT07232563Ischemic Stroke
Zhujiang Hospital
Phase 1
9
Guangzhou
2025-12-01
By invitation
Effects of tDCS on Fear Reversal in Patients With Anxiety Disorders
NCT07405463Anxiety Disorders
Jingchu Hu
Not applicable
140
Guangzhou
2025-12-01
Recruiting
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Not yet open
Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer
NCT07238959Benign Prostate Hypertrophy(BPH), Prostate Cancer (Diagnosis), Prostate Neoplasm
Shanghai Changzheng Hospital
Observational
1,100
Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo
2025-12
Not yet open
Impact of Computer-aided Detection System on the Proximal Adenoma Miss Rate
NCT07308743Colon Adenomas, Colon Polyps, Sessile Serrated Lesion
Nanfang Hospital, Southern Medical University
Not applicable
686
Guangzhou
2025-12
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
NCT07397819Malignant Ascites
Dong sheng Zhang
Phase 1/2
48
Guangzhou
2025-11-28
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Changde, Guangzhou, Hangzhou, Jiangmen, Luoyang
2025-11-28
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
NCT07278336Ovarian Cancer
AbbVie
Phase 1
219
Guangzhou, Jinan, Shanghai
2025-11-27
Recruiting
A Study of MHB042C in Patients With Advanced Solid Tumors
NCT07192107Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Guangzhou
2025-11-27
Recruiting
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha
2025-11-27
Recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.
Phase 2
75
Baotou, Beijing, Guangzhou, Hangzhou, Nanchang, Shenzhen
2025-11-26
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial
NCT07279077Colon Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiation Therapy
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
38
Guangzhou
2025-11-26
Not yet open
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
NCT07240376Non-Allergic Rhinitis With Eosinophilia Syndrome
Huazhong University of Science and Technology
Not applicable
90
Guangzhou, Wuhan, Xiangyang, Nanchang, Chengdu, Beijing, Shanghai
2025-11-25
Recruiting
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
NCT07269899Solid Tumor Cancer, Cancer
Sun Yat-sen University
Phase 1
12
Guangzhou
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 1/2
152
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Jinan, Shanghai, Shenyang
2025-11-24
Recruiting
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
NCT07229729Non-small Cell Lung Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
300
Guangzhou
2025-11-24
Recruiting
Comparison of the Efficacy and Safety of Ciprofol Versus Propofol for Sedation in ICU Patients Undergoing Non-Invasive Ventilation
NCT07536750Respiratory Failure, Critical Illness
Nanfang Hospital, Southern Medical University
Observational
1,680
Guangzhou
2025-11-24
Not yet open
A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
NCT07254156Colorectal Cancer, MRD, ctDNA
Sun Yat-sen University
Observational
229
Guangzhou
2025-11-24
Recruiting
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
NCT07208058Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
TJ Biopharma Co., Ltd.
Phase 3
30
Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang
2025-11-21
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
NCT07389629Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
25
Guangzhou
2025-11-21
Recruiting
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
NCT07650084Refractory Chronic Cough
GlaxoSmithKline
Phase 3
75
Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou
2025-11-21
Recruiting
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
NCT07241793Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent
Sun Yat-sen University
Phase 2
96
Guangzhou, Wuhan, Nanchang, Kunming
2025-11-20
Recruiting
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
NCT07328854Nasopharyngeal Carcinoma
Ming-Yuan Chen
Phase 3
346
Hefei, Fuzhou, Guangzhou, Shantou, Zhongshan, Zhuhai, Nanning, Wuzhou
2025-11-20
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Beijing, Chongqing, Guangzhou, Wuhan, Hangzhou
2025-11-19
Not yet open
A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
NCT07249892Metastatic Solid Tumors
Chengdu Syncor Pharmaceutical Co., Ltd.
Phase 1/2
195
Guangzhou
2025-11-19
Active, closed
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
NCT07216976Parkinson's Disease
MedtronicNeuro
Not applicable
61
Beijing, Guangzhou, Shanghai, Chengdu
2025-11-19
Recruiting
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
NCT07328841Nasopharyngeal Carcinoma (NPC)
Ming-Yuan Chen
Phase 3
456
Guangzhou, Shantou, Zhongshan, Nanning, Wuzhou, Wuhan, Changsha, Guangdong
2025-11-18
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
Summit Therapeutics
Phase 3
600
Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Haikou, Shijiazhuang, Harbin
2025-11-18
Active, closed
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
NCT07201337Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
NCT07161388Limited Stage Small-Cell Lung Cancer
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer
NCT07286240Treatment of Recurrent Ovarian Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2
40
Guangzhou
2025-11-15
Recruiting
Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss
NCT07505667Sudden Hearing Loss, Sensorineural Hearing Loss
Guangdong Provincial People's Hospital
Not applicable
128
Guangzhou, Shenzhen, Zhongshan, Liuzhou, Ganzhou
2025-11-15
Recruiting
Sepsis-associated Thrombocytopenia and Platelet Transfusion ๏ผˆSTAPT๏ผ‰
NCT07230067Sepsis, Sepsis and Coagulopathy
Nanfang Hospital, Southern Medical University
Observational
1,500
Guangzhou
2025-11-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
NCT07258108Breast Cancer
Sun Yat-sen University
Phase 2
35
Guangzhou
2025-11-13
Recruiting
HS-20117-2 Injection in Patients With Advanced Solid Tumors
NCT07775703Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1
60
Guangzhou
2025-11-13
Recruiting
A Study of DEG6498 in Participants With Solid Tumors
NCT07244835Malignant Neoplasms
Degron Therapeutics Co.
Phase 1
100
Beijing, Guangzhou
2025-11-13
Recruiting
Adaptive Immunotherapy for Nasopharyngeal Carcinoma
NCT07154069Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
802
Guangzhou
2025-11-13
Recruiting
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
83
Guangzhou, Tianjin
2025-11-12
Recruiting
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
NCT07241767Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
200
Guangzhou
2025-11-12
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang, Yinchuan
2025-11-11
Recruiting
Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC
NCT06998758Neoadjuvant Chemotherapy, Weight Loss
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3
60
Guangzhou
2025-11-11
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT07215585Large B-cell Lymphoma
AstraZeneca
Phase 3
420
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hefei
2025-11-11
Recruiting
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
NCT07232420Non Small Cell Lung Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou
2025-11-11
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161ANCA Associated Vasculitis (AAV)
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
300
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Meizhou, Shaoguan, Shenzhen
2025-11-10
Active, closed
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT07073820Pulmonary Hypertension
Pfizer
Phase 2
42
Guangzhou, Changsha, Nanjing, Shanghai
2025-11-10
Recruiting
Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza
NCT07357051Respiratory Viral Infection
Joincare Pharmaceutical Group Industry Co., Ltd
Phase 3
177
Guangzhou
2025-11-07
Recruiting
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
NCT07211542Moderate-to-severe Atopic Dermatitis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
75
Guangzhou
2025-11-07
Active, closed
A Parental Support Intervention for Children's Nature-Based Physical Activity: A Randomized Controlled Trial
NCT07674641Health Behavior, Physical Activity Promotion
South China Normal University
Not applicable
90
Guangzhou
2025-11-06
Recruiting
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
NCT07110415Coronary Heart Disease, Cardiac Dysfunction
SPH Qingdao Growful Pharmacetical Co.,Ltd
Phase 4
2,708
Haozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Zhuhai, Guilin
2025-11-06
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
Sanofi
Phase 2
208
Chengdu, Guangzhou, Shanghai, รœrรผmqi
2025-11-06
Recruiting
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD
NCT07351734COPD (Chronic Obstructive Pulmonary Disease)
Joincare Pharmaceutical Group Industry Co., Ltd
Phase 2
120
Guangzhou
2025-11-06
Active, closed
A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection
NCT07245953Chronic Hepatitis B
Suzhou HepaThera Biotech Co., Ltd.
Phase 2
60
Beijing, Fuzhou, Guangzhou, Qingyuan, Nanning, Zhengzhou, Nanjing, Zhenjiang
2025-11-05
Recruiting
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
NCT07238881Hepatocellulcar Carcinoma
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-11-05
Recruiting
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NCT07120698NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
Guangdong Association of Clinical Trials
Phase 2
115
Guangzhou, Chengdu
2025-11-05
Recruiting
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
NCT07258979Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
202
Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Guangzhou, Jiangmen, Shaoguan
2025-11-05
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
NCT07121413Idiopathic Pulmonary Fibrosis(IPF)
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Rows per page Showing 701–800 of 3318
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=8

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.